Sema Sezgin Göksu

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 364 citations

Oncology, Hepatology, Medicine +10

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Ying Cheng, David R. Spigel, Byoung Chul Cho et al. · New England Journal of Medicine · 2024 · 208 citations

Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study.

Meral Günaldı, Sema Sezgin Göksu, Di̇lek Erdem et al. · PubMed · 2015 · 51 citations · Full text

ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

David R. Spigel, Ying Cheng, Byoung Chul Cho et al. · Journal of Clinical Oncology · 2024 · 45 citations

Pathology, Consolidation Treatment, Treatment Verification +16

Hepatitis B reactivation related to everolimus

Sema Sezgin Göksu · World Journal of Hepatology · 2013 · 35 citations · Full text